Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Iceland

European Research Council grant · Running

Edit-SMM Early Detection and Intervention in Smoldering Multiple Myeloma: Population-based Screening and Treatment

Coordinator
Haskoli Islands, Iceland
Runs
1 June 2022 to 31 May 2027
Status
Running
EU funding
€2.0m
Total cost
€2.0m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101045549

What the project is doing

In the project's own words, from its summary on CORDIS.

Multiple myeloma (MM) is a bone marrow malignancy that is always preceded by asymptomatic precursor conditions, monoclonal gammopathy of undetermined significance (MGUS) or smoldering MM (SMM). SMM is a more advanced precursor and is associated with a high risk of progression to MM. More than 94% of MM cases are diagnosed when already at the stage of full-blown malignancy and therefore do not benefit from the impact of early treatment.

Recent studies indicate a benefit of early treatment but all prior SMM studies are based on patients diagnosed due to other medical issues and are therefore biased. There are important and urgent questions on the role of screening and early treatment in SMM. There is also an unmet need to develop a risk score for progression that considers the biology and genetics of the disease. In Edit-SMM we plan to build on the success from the Iceland Screens, Treats, or Prevents MM (iStopMM) study, where remarkably over 54% of the population (N=80,759) consented to a nationwide screening for MM precursors.

It includes clinical evaluation and follow-up, biobanking, cross linking to central health data registries, repeated questionnaires on patient reported outcomes, groundbreaking methods of detection of SMM, and in-depth genetics. Edit-SMM will identify all patients with SMM diagnosed in iStopMM. These will be followed and treated with the global objective of inducing a paradigm shift by improving diagnostics, disease classification, and population implementation of early intervention in MM by detecting and treating MM at a precursor state, hopefully leading to improved quality of life and potentially a cure.

The main objectives are to gather knowledge on the epidemiological, clinical, and patient reported outcomes of SMM, perform a unique nationwide early treatment trial, and leverage this unparalleled collection of samples to make major new discoveries on the biology and evolution of SMM.

Who is involved

OrganisationCityCountryRole
Haskoli IslandsReykjavikIcelandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI